Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

phenotyping

Accession Logo

Accession announces major UK market access consulting milestone

February 5th 2025: Today Accession Healthcare Consulting Ltd (Accession) has announced the achievement of a major consulting milestone as it enters its 15th year as a specialist provider of UK...

Accession

- PMLiVE

Kate Shaw comments the appointment of an independent review on clinical trials in the UK.

The news comes after a report by the Association of the British Pharmaceutical Industry (ABPI) highlighted a 44% decline in industry clinical trials in the UK over the last five...

Innovative Trials

- PMLiVE

J&J’s single-dose COVID-19 vaccine secures approval from the UK’s MHRA

Vaccine was found to be 67% effective in preventing COVID-19 infection in a phase 3 study

- PMLiVE

EU, UK working towards a ‘win-win’ situation to expand COVID-19 vaccine supplies

EU leaders are set to meet today to discuss proposed vaccine export plans

- PMLiVE

EU-UK COVID-19 vaccine row continues as export ban discussion looms

EU officials are set to discuss imposing a vaccine export ban this week

- PMLiVE

UK hits ‘significant milestone’ as 15 million people receive their first COVID-19 vaccine dose

The NHS also announced that five additional large-scale vaccination centres will open this week

- PMLiVE

New dosing option for AZ’s Imfinzi approved in the EU and UK

Additional option extends dosing from two weeks to four weeks

- PMLiVE

UK agrees on COVID-19 vaccine deals with J&J and Novavax

Initial agreement secures 90 million doses

- PMLiVE

NICE partially clears Darzalex combo in blood cancer

Approved in second-line use under  CDF

- PMLiVE

UK Biobank generates “largest open access resource of exome data”

Around 50,000 de-identifed genetic profiles available for research

“Brexit has been a catalyst for UK clinical research… it’s turbocharged change”

The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links